 |
|
Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream
A Prospective Study of 12 Cases
Jeanne Wendling, MD;
Philippe Saiag, MD, PhD;
Sophie Berville-Levy, MD;
Isabelle Bourgault-Villada, MD, PhD;
Thierry Clerici, MD;
Micheline Moyal-Barracco, MD
Arch Dermatol. 2004;140:1220-1224.
Objective To assess the efficacy of 5% imiquimod cream on undifferentiated vulvar intraepithelial neoplasia (VIN), a disease caused by high-risk human papillomavirus.
Design Prospective, uncontrolled study.
Setting University hospital vulvar clinic.
Patients Twelve consecutive patients treated with 5% imiquimod cream for undifferentiated VIN between March 1, 1999, and May 31, 2001.
Intervention Self-application of 5% imiquimod cream, initially 3 times a week, then adjusted according to tolerance, for up to 7 months according to clinical response.
Main Outcome Measures Therapeutic response, clinically assessed by successive photographs and histologically confirmed for complete responders, was scored as complete, partial ( 50% decrease in lesion size), or failure. Tolerance was evaluated at each visit.
Results A total of 3, 4, and 5 patients achieved complete response, partial response (75% reduction in lesion size for all such cases), and failure, respectively. Mean duration of treatment was 3.6 months (37.3 applications), 5.0 months (50.7 applications), and 3.4 months (25.2 applications) for complete responders, partial responders, and failures, respectively. Follow-up after treatment was 5 to 18, 14 to 32, and 2 to 28 months, respectively, with 1 partial responder lost to long-term follow-up. No patient developed invasive carcinoma. All but 2 patients experienced vulvar discomfort, resulting in treatment withdrawal for 3. Two patients had flulike symptoms.
Conclusions Imiquimod cream could be a therapeutic option for undifferentiated VIN. Although poorly tolerated, this self-applied treatment could spare patients, either totally or partially, the classic painful and sometimes mutilating treatments of VIN. Controlled, randomized studies are needed to evaluate its efficacy and tolerance.
From the Service de Dermatologie Générale et Oncologique (Drs Wendling, Saiag, Berville-Levy, Bourgault-Villada, and Moyal-Barracco) and Service d'Anatomopathologie (Dr Clerici), Hôpital Ambroise-Paré, Assistance Publique des Hôpitaux de Paris, Université Versailles Saint-Quentin en Yvelines, Boulogne, France. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment
van Poelgeest et al.
Clin. Cancer Res. 2005;11:5273-5280.
ABSTRACT
| FULL TEXT
|
